Publicacións nas que colabora con JAVIER SASTRE VALERA (8)

2017

  1. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  2. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

    Journal of the National Cancer Institute, Vol. 109, Núm. 4

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2014

  1. Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178

2013

  1. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study

    BMC Cancer, Vol. 13

  2. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. the large experience of the spanish national tumor registry (RGETNE)

    Neuroendocrinology, Vol. 98, Núm. 2, pp. 156-168

  3. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787

2010

  1. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)

    Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803